gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · ANIPHealthcarePharmaceuticals

ANI Pharmaceuticals, Inc. (ANIP)

$71.65−0.87%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$71.65▼ 24.16% in range
Nov 4, 2025Low $70.16 · High $94.48Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

ANI Pharmaceuticals closed at $71.65 on Nov 4, down 0.87%, within 2.1% of its 52-week closing low. Volume of 304.9K shares was 0.89× its 20-day average (close to normal).

Split-adjusted performance: +0.2% over one month, -14.8% over six months, -23.8% over one year.

In the quarter ended Jun 30, 2026, revenue was $266.04M, up 25.9% from a year earlier, with a net margin of 8.6%.

Short interest was 3.5M shares at the Oct 15 settlement (18.1% of float, 10.1 days to cover).

Market cap$1.65B23.0M shares
Revenue · quarter$266.0M+25.9% YoY
Diluted EPS$1.05+191.7% YoY
P/E · TTM16.5×P/S 1.7×
Net margin8.6%Gross 62.4%
Dividend yieldNone
52-week range70.16 – 94.48−24.2% from high
Volume304.9K0.89× 20-day avg
Volatility · 60d26.7%Annualised
Short % of float18.1%10.1 days to cover
Net cash-$234.7MCash $375.8M
Next earnings—Not scheduled
Split-adjusted performance
1W −0.1%1M +0.2%3M −13.3%6M −14.8%YTD −9.2%1Y −23.8%3Y +18.4%5Y +93.3%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum61
Revenue growth69
Net margin78
Value (low P/E)48
Size78

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short3.5M−0.6% vs prior
Days to cover10.1Settled Oct 15
% of float18.1%
Short vol. 10d64.8%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
ANIPANI Pharmaceuticals$71.65−0.87%−14.8%+25.9%8.6%16.5$1.65B
SUPNSupernus$28.21+0.21%−45.2%+18.0%9.2%—$1.64BCompare
KLRAKailera Therapeutics$12.80+1.75%————$1.66BCompare
NUVBNuvation Bio$4.73+0.85%−6.2%+555.6%−198.3%—$1.66BCompare
RAREUltragenyx Pharmaceutical$17.16+3.19%−33.8%+28.1%−43.0%—$1.69BCompare
PAHCPhibro Animal Health$39.43+4.73%−32.6%+4.8%5.5%16.1$1.60BCompare
QUREuniQure$23.03−3.52%+0.9%+11.0%−1387.8%—$1.60BCompare
OCULOcular Therapeutix$7.14+4.69%−26.5%+0.1%−584.5%—$1.57BCompare
NRIXNurix Therapeutics$15.95−38.23%−5.5%+8426.3%81.7%5.9$1.74BCompare

News about ANI Pharmaceuticals

All news →
Will ANI (ANIP) Beat Estimates Again in Its Next Earnings Report?Zacks Investment Research · Oct 13, 2026▲ PositiveANI Pharmaceuticals to Discuss Second Quarter 2026 Financial Results on August 7, 2026 at 8:00 a.m. ETGlobeNewswire Inc. · Jul 24, 2026▲ PositiveANI Pharmaceuticals Announces Positive Six-Month Topline Data from the Phase 4 Open-Label, Single-Arm SYNCHRONICITY Trial Evaluating Fluocinolone Acetonide Intravitreal Implant in Patients with Chronic Non-Infectious UveitisGlobeNewswire Inc. · Jul 13, 2026▲ PositiveANI Pharmaceuticals' CFO Sold $285,000 in Stock After a 32% RunThe Motley Fool · Jul 13, 2026NeutralGlobal Alpha Dumps 229,000 Ani Pharmaceuticals (ANIP) Shares Worth $17.9 MillionThe Motley Fool · May 11, 2026▼ Negative

Quick answers

What does ANI Pharmaceuticals do?
ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses.
What is ANIP's market cap?
$1.65B, based on the Nov 4 close of $71.65.
What is ANIP's P/E ratio?
16.5× trailing-twelve-month earnings of $99.61M.
Does ANI Pharmaceuticals pay a dividend?
No regular cash dividend has been paid in the last year.
How much of ANIP is sold short?
3.5M shares, 18.1% of float, as of Oct 15, 2026.
What sector is ANIP in?
Healthcare, in the Pharmaceuticals industry.

About ANI Pharmaceuticals

ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.

HQ: Princeton, NJ970 employeesListed Sep 13, 1999anipharmaceuticals.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology